EU Clears Ranolazine As CVT Bids For Broader U.S. Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Same cardiac safety data supports sNDA for first-line angina.
You may also be interested in...
CV Therapeutics Inks Ex-U.S. Ranexa Deal
With Menarini, angina drug will launch in the U.K. and Germany early next year.
CV Therapeutics Inks Ex-U.S. Ranexa Deal
With Menarini, angina drug will launch in the U.K. and Germany early next year.
FDA To Send Draft Ranexa Label Shortly
CV Therapeutics CEO is bullish on clearance in first-line angina.